Policy & Legislation

ATS Signs onto Coalition Letter in Support of Funding for Research Into Causes and Prevention of Gun Violence 

ATS Signs onto Coalition Letter in Support of Health Funding for FY2014 Budget Year 

ATS Supports Federal Legislation Aimed at Eliminating Drug Shortages

ATS Supported Legislation

ATS Signs onto Coalition Letter in Support of Funding for Research Into Causes and Prevention of Gun Violence  


(7/8/13) As a member of the Injury and Violence Prevention Coalition, the ATS joined a diverse group of health professionals, public health, and child advocacy organizations, to request Congressional support of research investments to address the public health crisis of gun violence.  The Coalition urged members of Congress to provide at least $10 million in new funding to the Centers for Disease Control and Prevention (CDC) in FY 2014 along with sufficient new funding at the National Institute of Health to support research into the causes and prevention of gun violence. 

On June 5, the Institute of Medicine released a report outlining a research agenda for addressing firearm-related injuries and deaths as a public health issue. The report highlights five key areas for research on this topic: characteristics of firearm violence; risk and protective factors; firearm violence prevention and other interventions; the impact of gun safety technology; and video games and other media. The IOM’s report notes that this agenda would be essential in supporting the development of policies to reduce the public health impact of firearms in the same manner as approaches that have found success in other areas, such as motor vehicle safety.

Funding at both CDC and NIH would be an important step toward realizing a robust research agenda and developing public health interventions that could protect children and keep them safe from gun violence.


Click Here to Read the Letter 

ATS Signs onto Coalition Letter in Support of Health Funding for FY2014 Budget Year. 


(2/19/13) Each year, a coalition of health organizations comes together in an effort to secure increased funding for health agencies and programs, including NIH, CDC, SAMHSA, HRSA, AHRQ, FDA, and the Indian Health Service, among others.  The coalition works collaboratively to secure a strong discretionary health funding allocation or “Function 550” in the budget resolution, which then increases the funds available for agency appropriations, which directly impacts your specific federal funding priorities


Early this year, lead by the Coalition for Health Funding, a summit was held with leaders of the health agency coalitions to develop a funding recommendation for FY 2014 Function 550.  The Health Summit recommends $65 billion for Function 550, a $7 billion increase over the Congressional Budget Office’s (CBO) estimated FY 2013 budget authority level of $58 billion. This request is consistent with the community’s FY 2012 Function 550 recommendation.


The coalition has drafted a letter to Congress to highlight this  recommendation.  To date, over 350 organizations, including the American Trauma Society have signed this letter to support health funding. 

Click here to read the letter.

ATS Supports Federal Legislation Aimed at Eliminating Drug Shortages


According to the Food and Drug Administration (FDA), the number of shortages for medically necessary drugs has tripled in the last six years—jumping from 61 products in 2005 to 178 in 2010. Trauma centers around the Nation currently face shortages of at least 30 generic drugs that are commonly used to care for critically ill and injured patients. 


The American Trauma Society has been actively involved in stakeholder meetings and supporting federal legislation that empowers the FDA to better monitor and resolve this situation. The Senate version of the "Food and Drug Administration Safety and Innovation Act” (S. 3187) passed the Senate May 24, 2012 and subsequently passed the House with changes on June 20, 2012. The final bill includes the following provisions aimed at alleviating the drug shortage:


Requires advanced notification by manufacturers to the FDA of potential drug shortages;

  • Mandates FDA to develop a drug shortage list, including information on reasons for the shortage, that would be made available to the public;
  • Expedite reviews of new drugs or supplement applications and facility inspections for drugs that are in danger of shortage;
  • Calls for the development of a strategic plan to address shortages and submit that plan to Congress;
  • Requires the Drug Enforcement Administration (DEA) to provide timely approvals or denials of increases in quotas of controlled substances in instances where such an increase could help address a drug shortage, and to report annually on their efforts on drug shortages based on the metrics set forth by Congress;
  • Allows hospitals within the same health system to repackage drugs into smaller units to alleviate drug shortages; and
  • Requires GAO to report on market factors contributing to drug shortages.
Lawmakers will attempt to quickly pass the bill as they have been aiming to complete the process by July 4, ahead of a Supreme Court ruling on health reform. The final user fee and FDA reform legislation is expected to come to a vote in the Senate early this week, and represents the final word on several FDA policy issues that have been the subject of intense lobbying in recent weeks.